Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

Nature Communications

Volumn 2, Issue 1, 2011, Pages

  Raab, Monika ^a,b   Kappel, Sven ^a   Krämer, Andrea ^a   Sanhaji, Mourad ^a   Matthess, Yves ^a   Kurunci Csacsko, Elisabeth ^a   Calzada Wack, Julia ^b   Rathkolb, Birgit ^b,c   Rozman, Jan ^b,d   Adler, Thure ^b,d   Busch, Dirk H ^d   Esposito, Irene ^b,d   Fuchs, Helmut ^b   Gailus Durner, Valérie ^b   Klingenspor, Martin ^d   Wolf, Eckhard ^c   Sänger, Nicole ^a   Prinz, Florian ^e   Angelis, Martin Hrabě De ^b,d   Seibler, Jost ^f   Yuan, Juping ^a   Bergmann, Martin ^g   Knecht, Rainald ^h   Kreft, Bertolt ^e   Strebhardt, Klaus ^a   more..

^a GOETHE UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e BAYER PHARMA AG   (Germany)

^f TaconicArtemis GmbH   (Germany)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POLO LIKE KINASE 1; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PRIMER DNA; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL CULTURE; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DEPLETION; FEMALE; GENE SILENCING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MAMMAL CELL; MOUSE; NONHUMAN; REVIEW; SPINDLE CELL; TOXICITY; ANIMAL; ARTICLE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE DOSAGE; GENETIC TRANSFECTION; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; NORTHERN BLOTTING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TOXICITY TESTING; TRANSGENIC MOUSE;

MAMMALIA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, NORTHERN; CELL CYCLE PROTEINS; CELLS, CULTURED; DNA PRIMERS; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE DOSAGE; GENE KNOCKDOWN TECHNIQUES; GENETIC ENGINEERING; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TOXICITY TESTS; TRANSFECTION;

EID: 79960580428     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1395     Document Type: Review

References (53)

1. Walrath, J. C., Hawes, J. J., Van, D. T. & Reilly, K. M. Genetically engineered mouse models in cancer research. Adv. Cancer Res. 106, 113-164 (2010
2. Sharpless, N. E. & DePinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5, 741-754 (2006 (Pubitemid 44323701)
3. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001 (Pubitemid 32494397)
4. Van, D. T. & Jacks, T. Cancer modeling in the modern era: progress and challenges. Cell 108, 135-144 (2002 (Pubitemid 34161134)
5. Jackson, J. R., Patrick, D. R., Dar, M. M. & Huang, P. S. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat. Rev. Cancer 7, 107-117 (2007 (Pubitemid 46160987)
6. Strebhardt, K. & Ullrich, A. Paul Ehrlichs magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473-480 (2008 (Pubitemid 351752547)
7. Yuan, J. et al. Polo-like kinase, a novel marker for cellular proliferation. Am. J. Pathol. 150, 1165-1172 (1997 (Pubitemid 27152634)
8. Barr, F. A., Sillje, H. H. & Nigg, E. A. Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 5, 429-440 (2004 (Pubitemid 38745493)
9. Strebhardt, K. & Ullrich, A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6, 321-330 (2006
10. Eckerdt, F., Yuan, J. & Strebhardt, K. Polo-like kinases and oncogenesis. Oncogene 24, 267-276 (2005 (Pubitemid 40188607)
11. Ahr, A. et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359, 131-132 (2002 (Pubitemid 34112543)
12. Yuan, J. et al. Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 21, 8282-8292 (2002 (Pubitemid 35477868)
13. Petronczki, M., Lenart, P. & Peters, J. M. Polo on the rise-from mitotic entry to Cytokinesis with Plk1. Dev. Cell 14, 646-659 (2008 (Pubitemid 351622626)
14. Archambault, V. & Glover, D. M. Polo-like kinases: conservation and divergence in their functions and regulation. Nat. Rev. Mol. Cell Biol. 10, 265-275 (2009
15. Lens, S. M., Voest, E. E. & Medema, R. H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 10, 825-841 (2010
16. Strebhardt, K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov. 9, 643-660 (2010
17. Lu, L. Y. et al. Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol. Cell Biol. 28, 6870-6876 (2008
18. Matthess, Y. et al. Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1. Oncogene 24, 2973-2980 (2005 (Pubitemid 40675528)
19. Kappel, S., Matthess, Y., Kaufmann, M. & Strebhardt, K. Silencing of mammalian genes by tetracycline-inducible shRNA expression. Nat. Protoc. 2, 3257-3269 (2007
20. Seibler, J. et al. Single copy shRNA configuration for ubiquitous gene knockdown in mice. Nucleic Acids Res. 33, e67 (2005
21. Seibler, J. et al. Reversible gene knockdown in mice using a tight, inducible shRNA expression system. Nucleic Acids Res. 35, e54 (2007
22. Lee, K. S. & Erikson, R. L. Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol. Cell Biol. 17, 3408-3417 (1997 (Pubitemid 27215056)
23. Ouyang, B. et al. Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions. J. Biol. Chem. 272, 28646-28651 (1997 (Pubitemid 27517819)
24. Gailus-Durner, V. et al. Introducing the German Mouse Clinic: open access platform for standardized phenotyping. Nat. Methods 2, 403-404 (2005 (Pubitemid 40916545)
25. Herrmann, S., Amorim, I. & Sunkel, C. E. The POLO kinase is required at multiple stages during spermatogenesis in Drosophila melanogaster. Chromosoma 107, 440-451 (1998 (Pubitemid 29057537)
26. de Rooij, D. G. & Russell, L. D. All you wanted to know about spermatogonia but were afraid to ask. J. Androl. 21, 776-798 (2000
27. Clermont, Y. & Trott, M. Duration of the cycle of the seminiferous epithelium in the mouse and hamster determined by means of 3H-thymidine and radioautography. Fertil. Steril. 20, 805-817 (1969
28. Petkova, S. B. et al. Genetic influence on immune phenotype revealed strain-specific variations in peripheral blood lineages. Physiol. Genomics 34, 304-314 (2008 (Pubitemid 352758845)
29. Wish, J. B. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin. J. Am. Soc. Nephrol. 1 (Suppl 1), S4-S8 (2006
30. Spankuch, B. et al. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J. Natl Cancer Inst. 96, 862-872 (2004 (Pubitemid 38807607)
31. Spankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M. & Strebhardt, K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl Cancer Inst. 94, 1863-1877 (2002 (Pubitemid 36104631)
32. Spankuch, B., Kurunci-Csacsko, E., Kaufmann, M. & Strebhardt, K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 26, 5793-5807 (2007 (Pubitemid 47312808)
33. Kreis, N. N. et al. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle 8, 460-472 (2009
34. Qian, Y. W., Erikson, E., Taieb, F. E. & Maller, J. L. The polo-like kinase Plx1 is required for activation of the phosphatase Cdc25C and cyclin B-Cdc2 in Xenopus oocytes. Mol. Biol. Cell 12, 1791-1799 (2001 (Pubitemid 33049730)
35. Sunkel, C. E. & Glover, D. M. Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J. Cell Sci. 89 (Part 1), 25-38 (1988
36. Lane, H. A. & Nigg, E. A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J. Cell Biol. 135, 1701-1713 (1996 (Pubitemid 27036434)
37. Musacchio, A. & Salmon, E. D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 8, 379-393 (2007 (Pubitemid 46643240)
38. Gascoigne, K. E. & Taylor, S. S. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14, 111-122 (2008
39. Rieder, C. L. & Maiato, H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell 7, 637-651 (2004 (Pubitemid 39462685)
40. Guan, R. et al. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res. 65, 2698-2704 (2005 (Pubitemid 40490070)
41. Liu, X., Lei, M. & Erikson, R. L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol. Cell Biol. 26, 2093-2108 (2006 (Pubitemid 43346913)
42. Steegmaier, M. et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 17, 316-322 (2007 (Pubitemid 46241881)
43. Solter, D. From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research. Nat. Rev. Genet. 7, 319-327 (2006
44. Olmos, D., Swanton, C. & de, B. J. Targeting polo-like kinase: learning too little too late? J. Clin. Oncol. 26, 5497-5499 (2008
45. Lu, B. et al. The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. PLoS One 5, e12963 (2010
46. Farwell, D. G. et al. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. Am. J. Pathol. 156, 1537-1547 (2000 (Pubitemid 30646693)
47. Sukhacheva, T. V., Bogush, T. A. & Kolomiets, O. L. Damaging effect of taxol on mouse spermatogenesis. Bull. Exp. Biol. Med. 132, 1087-1092 (2001 (Pubitemid 34295940)
48. Carmena, M. et al. Drosophila polo kinase is required for cytokinesis. J. Cell Biol. 143, 659-671 (1998 (Pubitemid 28512562)
49. Mross, K. et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 26, 5511-5517 (2008
50. Schoffski, P. et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur. J. Cancer 46, 2206-2215 (2010
51. Blat, C., Villaudy, J. & Harel, L. Density-dependent inhibition of mouse embryo fibroblast growth: involvement of IGFBP-3. Exp. Cell Res. 215, 114-118 (1994 (Pubitemid 24339181)
52. Raab, M. et al. T cell receptor inside-out pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity 32, 541-556 (2010
53. Matthess, Y., Raab, M., Sanhaji, M., Lavrik, I. N. & Strebhardt, K. Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol. Cell Biol. 30, 5726-5740 (2010)